Hyaluronic acid (topical)

{{DrugProjectFormSinglePage |authorTag=Kiran Singh, M.D. [1] |genericName=hyaluronic acid |aOrAn=a |drugClass=musculoskeletal agent |indicationType=treatment |indication=osteoarthritis of knee, hair growth and loss prevention |adverseReactions=injection site pain, injection site reaction , arthralgia |blackBoxWarningTitle=ConditionName: |blackBoxWarningBody=ConditionName:

• Content

|fdaLIADAdult===Indications==

Hyaluronic Acid Solution

• For hair grower and loss prevention

Dosage

• Spray on the scalp 2~3 times daily as needed
• Recommendable to apply enough on the scalp prior to going to bed

Hyaluronic Acid Injection

• Osteoarthritis of knee

Dosage

• Osteoarthritis of knee: 30 mg per 2 mL (contents of prefilled syringe) INTRA-ARTICULARLY into the knee once weekly for a total of 3 to 4 injections (as a series of 3 to 4 injections each 1 week apart).

|offLabelAdultGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Hyaluronic acid (topical) in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Hyaluronic acid (topical) in adult patients. |fdaLIADPed=There is limited information regarding FDA-Labeled Use of Hyaluronic acid (topical) in pediatric patients. |offLabelPedGuideSupport=There is limited information regarding Off-Label Guideline-Supported Use of Hyaluronic acid (topical) in pediatric patients. |offLabelPedNoGuideSupport=There is limited information regarding Off-Label Non–Guideline-Supported Use of Hyaluronic acid (topical) in pediatric patients. |warnings=* Stop using and see a doctor if any hypersensitivity symptom continues

• Avoid storing under direct sung light or high temperature

|clinicalTrials=Dermatologic: Injection site pain, Injection site reaction

Musculoskeletal: arthralgia |postmarketing=There is limited information regarding Postmarketing Experience of Hyaluronic acid (topical) in the drug label. |useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Hyaluronic acid (topical) in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of Hyaluronic acid (topical) during labor and delivery. |useInNursing=There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to nursing mothers. |useInPed=There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to pediatric patients. |useInGeri=There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Hyaluronic acid (topical) with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of Hyaluronic acid (topical) in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of Hyaluronic acid (topical) in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Hyaluronic acid (topical) in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Hyaluronic acid (topical) in patients who are immunocompromised.

|administration=* IV Attach a small gauge needle (18- to 21-gauge) to tip of the syringe; inject the full contents of syringe into one knee only.

If treatment is bilateral, use a separate syringe for each knee.

• For hair scalp spraying only

|monitoring=* Reduction in pain associated with osteoarthritis of the knee is indicative of efficacy |IVCompat=There is limited information regarding IV Compatibility of Hyaluronic acid (topical) in the drug label. |drugBox=